Skip to main content
Top
Published in: Current HIV/AIDS Reports 3/2019

01-06-2019 | Human Immunodeficiency Virus | Central Nervous System and Cognition (S Spudich, Section Editor)

Neurocognitive Phenotyping of HIV in the Era of Antiretroviral Therapy

Author: Robert Paul

Published in: Current HIV/AIDS Reports | Issue 3/2019

Login to get access

Abstract

Purpose of Review

This paper examines the theoretical and empirical basis for neurocognitive phenotyping of HIV.

Recent Findings

The pattern of neurocognitive symptoms associated with HIV has traditionally been referred to as a “subcortical” phenotype. Recent concern has been raised that the neurocognitive phenotype in the post-ART era has changed to reflect the addition of cortical features, suggestive of synergistic age-related neurodegeneration. Empirical evidence reviewed in this paper suggests that, when present, HIV-related neurocognitive impairment in the post-ART era remains subcortical in nature, regardless of advanced age or treatment status. Persistent neurocognitive impairment among virally suppressed individuals may reflect a combination of HIV disease factors, pre-existing risk factors, and/or emergent health comorbidities such as subcortical ischemic vascular disease in older people living with HIV.

Summary

An entrenchment of the subcortical neurocognitive phenotype of HIV appears to be unfolding in the post-ART era. Whether new neurocognitive subtypes of HIV exist in the current era requires additional research utilizing harmonized test protocols and advanced computational methods capable of deep phenotyping. Recommendations from other neurological disorders are provided.
Literature
1.
go back to reference Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy CHARTER study. Neurol. 2010;75(23):2087–96.CrossRef Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy CHARTER study. Neurol. 2010;75(23):2087–96.CrossRef
3.
go back to reference Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–99.CrossRefPubMed Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–99.CrossRefPubMed
4.
go back to reference Valcour V, Sithinamsuwan P, Letendre S, Ances B. Pathogenesis of HIV in the central nervous system. Current HIV/AIDS Reports. 2011;8(1):54–61.5.CrossRefPubMed Valcour V, Sithinamsuwan P, Letendre S, Ances B. Pathogenesis of HIV in the central nervous system. Current HIV/AIDS Reports. 2011;8(1):54–61.5.CrossRefPubMed
5.
go back to reference Grant I, Franklin DR, Deutsch R, Woods SP, Vaida F, Ellis RJ, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurol. 2014;82(23):2055–62.CrossRef Grant I, Franklin DR, Deutsch R, Woods SP, Vaida F, Ellis RJ, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurol. 2014;82(23):2055–62.CrossRef
6.
go back to reference Saylor D, Dickens AM, Sacktor N, Haughey N, Slusher B, Pletnikov M, et al. HIV-associated neurocognitive disorder—pathogenesis and prospects for treatment. Nat Rev Neurol. 2016;12(4):234.CrossRefPubMedPubMedCentral Saylor D, Dickens AM, Sacktor N, Haughey N, Slusher B, Pletnikov M, et al. HIV-associated neurocognitive disorder—pathogenesis and prospects for treatment. Nat Rev Neurol. 2016;12(4):234.CrossRefPubMedPubMedCentral
7.
go back to reference Sacktor N, Nakasujja N, Skolasky R, Robertson K, Wong M, Musisi S, et al. Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa. Neurology. 2006;67(2):311–4.CrossRefPubMed Sacktor N, Nakasujja N, Skolasky R, Robertson K, Wong M, Musisi S, et al. Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa. Neurology. 2006;67(2):311–4.CrossRefPubMed
8.
go back to reference Cardenas VA, Meyerhoff DJ, Studholme C, Kornak J, Rothlind J, Lampiris H, et al. Evidence for ongoing brain injury in human immunodeficiency virus–positive patients treated with antiretroviral therapy. J Neuro-Oncol. 2009;15(4):324–33. Cardenas VA, Meyerhoff DJ, Studholme C, Kornak J, Rothlind J, Lampiris H, et al. Evidence for ongoing brain injury in human immunodeficiency virus–positive patients treated with antiretroviral therapy. J Neuro-Oncol. 2009;15(4):324–33.
9.
go back to reference Cohen RA, Harezlak J, Schifitto G, Hana G, Clark U, Gongvatana A, et al. Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era. J Neuro-Oncol. 2010;16(1):25–32. Cohen RA, Harezlak J, Schifitto G, Hana G, Clark U, Gongvatana A, et al. Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era. J Neuro-Oncol. 2010;16(1):25–32.
10.
go back to reference • Sanford R, Ances BM, Meyerhoff DJ, Price RW, Fuchs D, Zetterberg H, et al. Longitudinal trajectories of brain volume and cortical thickness in treated and untreated primary human immunodeficiency virus infection. Clin Infect Dis. 2018;67(11):1697–704. Initiation of ART in early infection did not reverse existing brain abnormalities but provided protection against progressive brain injury for a short period of time. Additional studies are needed to determine the durability of these findings. CrossRefPubMedPubMedCentral • Sanford R, Ances BM, Meyerhoff DJ, Price RW, Fuchs D, Zetterberg H, et al. Longitudinal trajectories of brain volume and cortical thickness in treated and untreated primary human immunodeficiency virus infection. Clin Infect Dis. 2018;67(11):1697–704. Initiation of ART in early infection did not reverse existing brain abnormalities but provided protection against progressive brain injury for a short period of time. Additional studies are needed to determine the durability of these findings. CrossRefPubMedPubMedCentral
11.
go back to reference Kallianpur KJ, Colby D, Jahanshad N, Fletcher JK, Ananworanich J, Clifford K, Benjapornpong K, Adams C, Spudich S, Valcour V for the RV254/S010 protocol teams. Brain volumetric changes after two years of ART initiated during acute HIV Infection. 23rd Conference on Retroviruses and Opportunistic Infections, February 22–25, 2016, Boston (Poster). Kallianpur KJ, Colby D, Jahanshad N, Fletcher JK, Ananworanich J, Clifford K, Benjapornpong K, Adams C, Spudich S, Valcour V for the RV254/S010 protocol teams. Brain volumetric changes after two years of ART initiated during acute HIV Infection. 23rd Conference on Retroviruses and Opportunistic Infections, February 22–25, 2016, Boston (Poster).
12.
go back to reference Sacktor N, Robertson K. Evolving clinical phenotypes in HIV-associated neurocognitive disorders. Current HIV/ AIDS Reports. 2014;9(6):517.CrossRef Sacktor N, Robertson K. Evolving clinical phenotypes in HIV-associated neurocognitive disorders. Current HIV/ AIDS Reports. 2014;9(6):517.CrossRef
13.
go back to reference • Sacktor N. Changing clinical phenotypes of HIV-associated neurocognitive disorders. J Neuro-Oncol. 2017;27:1–5. Treatment with ART has decreased the severity of HAND, but symptoms persist with evidence of cortical and subcortical features. Vascular mechanisms and other comorbidities likely contribute to the expression of symptoms in treatment-experienced individuals. • Sacktor N. Changing clinical phenotypes of HIV-associated neurocognitive disorders. J Neuro-Oncol. 2017;27:1–5. Treatment with ART has decreased the severity of HAND, but symptoms persist with evidence of cortical and subcortical features. Vascular mechanisms and other comorbidities likely contribute to the expression of symptoms in treatment-experienced individuals.
14.
go back to reference Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol. 1986;19(6):517–24.CrossRefPubMed Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol. 1986;19(6):517–24.CrossRefPubMed
15.
go back to reference Paul RH, Ernst T, Brickman AM, Yiannoutsos CT, Tate DF, Cohen RA, et al. Relative sensitivity of magnetic resonance spectroscopy and quantitative magnetic resonance imaging to cognitive function among nondemented individuals infected with HIV. JINS. 2008;14(5):725–33.PubMed Paul RH, Ernst T, Brickman AM, Yiannoutsos CT, Tate DF, Cohen RA, et al. Relative sensitivity of magnetic resonance spectroscopy and quantitative magnetic resonance imaging to cognitive function among nondemented individuals infected with HIV. JINS. 2008;14(5):725–33.PubMed
16.
go back to reference Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, LeBlanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurvirol. 2011;17(1):3–16.CrossRef Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, LeBlanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurvirol. 2011;17(1):3–16.CrossRef
17.
go back to reference Woods SP, Iudicello JE, Moran LM, Carey CL, Dawson MS, Grant I. HIV-associated prospective memory impairment increases risk of dependence in everyday functioning. Neuropsychol. 2008;22(1):110.CrossRef Woods SP, Iudicello JE, Moran LM, Carey CL, Dawson MS, Grant I. HIV-associated prospective memory impairment increases risk of dependence in everyday functioning. Neuropsychol. 2008;22(1):110.CrossRef
18.
go back to reference Archibald SL, Masliah E, Fennema-Notestine C, Marcotte TD, Ellis RJ, McCutchan JA, et al. Correlation of in vivo neuroimaging abnormalities with postmortem human immunodeficiency virus encephalitis and dendritic loss. Arch Neurol. 2004;61(3):369–76.CrossRefPubMed Archibald SL, Masliah E, Fennema-Notestine C, Marcotte TD, Ellis RJ, McCutchan JA, et al. Correlation of in vivo neuroimaging abnormalities with postmortem human immunodeficiency virus encephalitis and dendritic loss. Arch Neurol. 2004;61(3):369–76.CrossRefPubMed
19.
go back to reference Becker JT, Sanders J, Madsen SK, Ragin A, Kingsley L, Maruca V, et al. Subcortical brain atrophy persists even in HAART-regulated HIV disease. Brain Imaging Behav. 2011;5(2):77–85.CrossRefPubMedPubMedCentral Becker JT, Sanders J, Madsen SK, Ragin A, Kingsley L, Maruca V, et al. Subcortical brain atrophy persists even in HAART-regulated HIV disease. Brain Imaging Behav. 2011;5(2):77–85.CrossRefPubMedPubMedCentral
20.
go back to reference Paul R, Cohen R, Navia B, Tashima K. Relationships between cognition and structural neuroimaging findings in adults with human immunodeficiency virus type-1. Neurosci Biobehav Rev. 2002;26(3):353–9.CrossRefPubMed Paul R, Cohen R, Navia B, Tashima K. Relationships between cognition and structural neuroimaging findings in adults with human immunodeficiency virus type-1. Neurosci Biobehav Rev. 2002;26(3):353–9.CrossRefPubMed
21.
go back to reference Wright PW, Vaida FF, Fernández RJ, Rutlin J, Price RW, Lee E, et al. Cerebral white matter integrity during primary HIV infection. AIDS (London, England). 2015;29(4):433.CrossRef Wright PW, Vaida FF, Fernández RJ, Rutlin J, Price RW, Lee E, et al. Cerebral white matter integrity during primary HIV infection. AIDS (London, England). 2015;29(4):433.CrossRef
22.
go back to reference Paul RH, Yiannoutsos CT, Miller EN, Chang L, Marra CM, Schifitto G, et al. Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificity. J Neuropsych Clin Neurosci. 2007;19(3):283–92.CrossRef Paul RH, Yiannoutsos CT, Miller EN, Chang L, Marra CM, Schifitto G, et al. Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificity. J Neuropsych Clin Neurosci. 2007;19(3):283–92.CrossRef
23.
go back to reference Thompson PM, Dutton RA, Hayashi KM, Toga AW, Lopez OL, Aizenstein HJ, et al. Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline. PNAS. 2005;102(43):15647–52.CrossRefPubMedPubMedCentral Thompson PM, Dutton RA, Hayashi KM, Toga AW, Lopez OL, Aizenstein HJ, et al. Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline. PNAS. 2005;102(43):15647–52.CrossRefPubMedPubMedCentral
24.
go back to reference Baker LM, Cooley SA, Cabeen RP, Laidlaw DH, Joska JA, Hoare J, et al. Topological organization of whole-brain white matter in HIV infection. Brain Connectivity. 2017;7(2):115–22.CrossRefPubMedPubMedCentral Baker LM, Cooley SA, Cabeen RP, Laidlaw DH, Joska JA, Hoare J, et al. Topological organization of whole-brain white matter in HIV infection. Brain Connectivity. 2017;7(2):115–22.CrossRefPubMedPubMedCentral
25.
go back to reference Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre-and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neuro-Oncol. 2004;10(6):350–7. Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre-and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neuro-Oncol. 2004;10(6):350–7.
26.
go back to reference Solomon IH, De Girolami U, Chettimada S, Misra V, Singer EJ, Gabuzda D. Brain and liver pathology, amyloid deposition, and interferon responses among older HIV-positive patients in the late HAART era. BMC Infect Dis. 2017;17(1):151.CrossRefPubMedPubMedCentral Solomon IH, De Girolami U, Chettimada S, Misra V, Singer EJ, Gabuzda D. Brain and liver pathology, amyloid deposition, and interferon responses among older HIV-positive patients in the late HAART era. BMC Infect Dis. 2017;17(1):151.CrossRefPubMedPubMedCentral
27.
go back to reference van Gorp WG, Hinkin C, Satz P, Miller EN, Weisman J, Holston S, et al. Subtypes of HIV-related neuropsychological functioning: a cluster analysis approach. Neuropsychol. 1993;7(1):62.CrossRef van Gorp WG, Hinkin C, Satz P, Miller EN, Weisman J, Holston S, et al. Subtypes of HIV-related neuropsychological functioning: a cluster analysis approach. Neuropsychol. 1993;7(1):62.CrossRef
28.
go back to reference Fazeli PL, Crowe M, Ross LA, Wadley V, Ball K, Vance DE. Cognitive functioning in adults aging with HIV: a cross-sectional analysis of cognitive subtypes and influential factors. J Clin Res HIV AIDS Prev. 2014;1(4):155.CrossRefPubMedPubMedCentral Fazeli PL, Crowe M, Ross LA, Wadley V, Ball K, Vance DE. Cognitive functioning in adults aging with HIV: a cross-sectional analysis of cognitive subtypes and influential factors. J Clin Res HIV AIDS Prev. 2014;1(4):155.CrossRefPubMedPubMedCentral
29.
go back to reference Lojek E, Bornstein RA. The stability of neurocognitive patterns in HIV infected men: classification considerations. J Clin Exp Neuropsychol. 2005;27(6):665–82.CrossRefPubMed Lojek E, Bornstein RA. The stability of neurocognitive patterns in HIV infected men: classification considerations. J Clin Exp Neuropsychol. 2005;27(6):665–82.CrossRefPubMed
30.
go back to reference Dawes S, Suarez P, Casey CY, Cherner M, Marcotte TD, Letendre S, et al. Variable patterns of neuropsychological performance in HIV-1 infection. J Clin Exp Neuropsychol. 2008;30(6):613–26.CrossRefPubMedPubMedCentral Dawes S, Suarez P, Casey CY, Cherner M, Marcotte TD, Letendre S, et al. Variable patterns of neuropsychological performance in HIV-1 infection. J Clin Exp Neuropsychol. 2008;30(6):613–26.CrossRefPubMedPubMedCentral
31.
go back to reference Molsberry SA, Cheng Y, Kingsley L, Jacobson L, Levine AJ, Martin E, et al. Neuropsychological phenotypes among men with and without HIV disease in the multicenter AIDS cohort study. AIDS. 2018;32(12):1679–88.CrossRefPubMed Molsberry SA, Cheng Y, Kingsley L, Jacobson L, Levine AJ, Martin E, et al. Neuropsychological phenotypes among men with and without HIV disease in the multicenter AIDS cohort study. AIDS. 2018;32(12):1679–88.CrossRefPubMed
32.
go back to reference Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, et al. National Institute of Neurological Disorders and Stroke–Canadian stroke network vascular cognitive impairment harmonization standards. Stroke. 2006;37(9):2220–41.CrossRefPubMed Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, et al. National Institute of Neurological Disorders and Stroke–Canadian stroke network vascular cognitive impairment harmonization standards. Stroke. 2006;37(9):2220–41.CrossRefPubMed
33.
go back to reference Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC. Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS (London, England). 2013;27(9):1387–95.CrossRef Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC. Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS (London, England). 2013;27(9):1387–95.CrossRef
34.
go back to reference D’Antoni ML, Byron MM, Chan P, Sailasuta N, Sacdalan C, Sithinamsuwan P, et al. Normalization of soluble CD163 after institution of antiretroviral therapy during acute HIV infection tracks with fewer neurological abnormalities. JID. 2018;8(9):1453–63.CrossRef D’Antoni ML, Byron MM, Chan P, Sailasuta N, Sacdalan C, Sithinamsuwan P, et al. Normalization of soluble CD163 after institution of antiretroviral therapy during acute HIV infection tracks with fewer neurological abnormalities. JID. 2018;8(9):1453–63.CrossRef
35.
go back to reference • Imp BM, Rubin LH, Tien PC, Plankey MW, Golub ET, French AL, et al. Monocyte activation is associated with worse cognitive performance in virologically suppressed HIV-infected women. JID. 2016;27:jiw506. Plasma levels of sCD163 corresponded to overall neurocognitive performance, memory, psychomotor speed, and motor function in females with chronic HIV on suppressive ART. Additionally, plasma levels of sCD164 correlated with performance on tests of executive function in aviremic females on ART. The results demonstrate that ongoing immune activation is associated with brain function in optimally treated individuals. • Imp BM, Rubin LH, Tien PC, Plankey MW, Golub ET, French AL, et al. Monocyte activation is associated with worse cognitive performance in virologically suppressed HIV-infected women. JID. 2016;27:jiw506. Plasma levels of sCD163 corresponded to overall neurocognitive performance, memory, psychomotor speed, and motor function in females with chronic HIV on suppressive ART. Additionally, plasma levels of sCD164 correlated with performance on tests of executive function in aviremic females on ART. The results demonstrate that ongoing immune activation is associated with brain function in optimally treated individuals.
36.
go back to reference Ndhlovu LC, Umaki T, Chew GM, Chow DC, Agsalda M, Kallianpur KJ, et al. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND). J Neuro-Oncol. 2014;20(6):571–82. Ndhlovu LC, Umaki T, Chew GM, Chow DC, Agsalda M, Kallianpur KJ, et al. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND). J Neuro-Oncol. 2014;20(6):571–82.
37.
go back to reference Ndhlovu LC, D'Antoni ML, Ananworanich J, Byron MM, Chalermchai T, Sithinamsuwan P, et al. Loss of CCR2 expressing non-classical monocytes are associated with cognitive impairment in antiretroviral therapy-naive HIV-infected Thais. J Neuroimmunol. 2015;288:25–33.CrossRefPubMedPubMedCentral Ndhlovu LC, D'Antoni ML, Ananworanich J, Byron MM, Chalermchai T, Sithinamsuwan P, et al. Loss of CCR2 expressing non-classical monocytes are associated with cognitive impairment in antiretroviral therapy-naive HIV-infected Thais. J Neuroimmunol. 2015;288:25–33.CrossRefPubMedPubMedCentral
38.
go back to reference Krebs SJ, Slike BM, Sithinamsuwan P, Allen IE, Chalermchai T, Tipsuk S, et al. Sex differences in soluble markers vary before and after the initiation of antiretroviral therapy in chronically HIV infected individuals. AIDS (London, England). 2016;30(10):1533.CrossRef Krebs SJ, Slike BM, Sithinamsuwan P, Allen IE, Chalermchai T, Tipsuk S, et al. Sex differences in soluble markers vary before and after the initiation of antiretroviral therapy in chronically HIV infected individuals. AIDS (London, England). 2016;30(10):1533.CrossRef
39.
go back to reference Ver Steeg G, Galstyan A. Discovering structure in high-dimensional data through correlation explanation. In Advances in Neural Information Processing Systems 2014. pp. 1004–1012. Ver Steeg G, Galstyan A. Discovering structure in high-dimensional data through correlation explanation. In Advances in Neural Information Processing Systems 2014. pp. 1004–1012.
40.
go back to reference Massa MS, Wang N, Bickerton WL, Demeyere N, Riddoch MJ, Humphreys GW. On the importance of cognitive profiling: a graphical modelling analysis of domain-specific and domain-general deficits after stroke. Cortex. 2015;71:190–204.CrossRefPubMed Massa MS, Wang N, Bickerton WL, Demeyere N, Riddoch MJ, Humphreys GW. On the importance of cognitive profiling: a graphical modelling analysis of domain-specific and domain-general deficits after stroke. Cortex. 2015;71:190–204.CrossRefPubMed
41.
go back to reference Li Y, Root JC, Atkinson TM, Ahles TA. Examining the association between patient-reported symptoms of attention and memory dysfunction with objective cognitive performance: a latent regression rasch model approach. Arch Clin Neuropsychol. 2016;31(4):365–77.CrossRefPubMedPubMedCentral Li Y, Root JC, Atkinson TM, Ahles TA. Examining the association between patient-reported symptoms of attention and memory dysfunction with objective cognitive performance: a latent regression rasch model approach. Arch Clin Neuropsychol. 2016;31(4):365–77.CrossRefPubMedPubMedCentral
42.
go back to reference Patton DE, Woods SP, Franklin D, Cattie JE, Heaton RK, Collier AC, et al. Relationship of medication management test-revised (MMT-R) performance to neuropsychological functioning and antiretroviral adherence in adults with HIV. AIDS Behav. 2012;16(8):2286–96.CrossRefPubMedPubMedCentral Patton DE, Woods SP, Franklin D, Cattie JE, Heaton RK, Collier AC, et al. Relationship of medication management test-revised (MMT-R) performance to neuropsychological functioning and antiretroviral adherence in adults with HIV. AIDS Behav. 2012;16(8):2286–96.CrossRefPubMedPubMedCentral
43.
go back to reference Woods SP, Iudicello JE, Morgan EE, Cameron MV, Doyle KL, Smith TV, et al. HIV neurobehavioral research program (HNRP) group, Grant I, Atkinson JH, Ellis RJ. Health-related everyday functioning in the internet age: HIV-associated neurocognitive disorders disrupt online pharmacy and health chart navigation skills. Arch Clin Neuropsychol. 2016;31(2):176–85.PubMedPubMedCentral Woods SP, Iudicello JE, Morgan EE, Cameron MV, Doyle KL, Smith TV, et al. HIV neurobehavioral research program (HNRP) group, Grant I, Atkinson JH, Ellis RJ. Health-related everyday functioning in the internet age: HIV-associated neurocognitive disorders disrupt online pharmacy and health chart navigation skills. Arch Clin Neuropsychol. 2016;31(2):176–85.PubMedPubMedCentral
Metadata
Title
Neurocognitive Phenotyping of HIV in the Era of Antiretroviral Therapy
Author
Robert Paul
Publication date
01-06-2019
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 3/2019
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-019-00426-9

Other articles of this Issue 3/2019

Current HIV/AIDS Reports 3/2019 Go to the issue

HIV Pathogenesis and Treatment (AL Landay and NS Utay, Section Editors)

Pathogenic Role of Type I Interferons in HIV-Induced Immune Impairments in Humanized Mice

HIV Pathogenesis and Treatment (AL Landay and NS Utay, Section Editors)

Lipidome Abnormalities and Cardiovascular Disease Risk in HIV Infection

The Science of Prevention (JD Stekler and JM Baeten, Section Editors)

Confronting Rising STIs in the Era of PrEP and Treatment as Prevention

HIV Pathogenesis and Treatment (AL Landay and NS Utay, Section Editors)

HIV and the Gut Microbiota: Composition, Consequences, and Avenues for Amelioration

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.